Steven M Chan
Overview
Explore the profile of Steven M Chan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
2251
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang Y, Cathelin S, Liu A, Subedi A, Maher A, Hosseini M, et al.
Nat Commun
. 2025 Mar;
16(1):2384.
PMID: 40064887
Ten-Eleven Translocation-2 (TET2) mutations drive the expansion of mutant hematopoietic stem cells (HSCs) in clonal hematopoiesis (CH). However, the precise mechanisms by which TET2 mutations confer a competitive advantage to...
2.
Liu A, Chan S
Bioinformatics
. 2024 Nov;
40(11).
PMID: 39504441
Summary: We present ADTGP, an R package that uses Gaussian process regression to correct droplet-specific technical noise in single-cell protein sequencing data. ADTGP improves the interpretability of the data by...
3.
Chiu M, Schimmer A, Schuh A, Bankar A, Richard-Carpentier G, Sibai H, et al.
Blood Cancer J
. 2024 Nov;
14(1):190.
PMID: 39482301
No abstract available.
4.
Perusini M, Andrews C, Atenafu E, Gupta V, Maze D, Schuh A, et al.
Hematology
. 2024 Mar;
29(1):2329027.
PMID: 38526239
This retrospective report presents the outcomes and adverse events (AEs) observed in 73 patients aged 60 years or older diagnosed with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia (Ph-negative ALL) treated with...
5.
Perusini M, Andrews C, Eshetu A, Gupta V, Maze D, Yee K, et al.
Leukemia
. 2024 Mar;
38(4):912-913.
PMID: 38431747
No abstract available.
6.
Hosseini M, Voisin V, Chegini A, Varesi A, Cathelin S, Manikoth Ayyathan D, et al.
Res Sq
. 2024 Feb;
PMID: 38405837
Clonal hematopoiesis (CH) arises when a hematopoietic stem cell (HSC) acquires a mutation that confers a competitive advantage over wild-type (WT) HSCs, resulting in its clonal expansion. Individuals with CH...
7.
Murphy T, Mason J, Leber B, Bray M, Chan S, Gupta V, et al.
Leukemia
. 2023 Dec;
38(3):502-512.
PMID: 38114624
CFI-400945 is a selective oral polo-like kinase 4 (PLK4) inhibitor that regulates centriole duplication. PLK4 is aberrantly expressed in patients with acute myeloid leukemia (AML). Preclinical studies indicate that CFI-400945...
8.
Murphy T, Zou J, Arruda A, Wang T, Zhao Z, Zheng Y, et al.
Haematologica
. 2023 Jun;
109(2):671-675.
PMID: 37345484
No abstract available.
9.
Hall V, Tang K, Kumar D, Rotstein C, Chow S, Chan S, et al.
Open Forum Infect Dis
. 2023 Apr;
10(3):ofad134.
PMID: 37008567
Venetoclax requires a 75% dose reduction when coadministered with voriconazole. In a 10-year historical cohort of treatment with venetoclax, we did not observe a worse hematologic outcome in patients who...
10.
Al Nabhani I, Andrews C, Sibai J, Atenafu E, Young T, Chan S, et al.
EJHaem
. 2023 Feb;
4(1):232-235.
PMID: 36819167
PEG-asparaginase is used as a treatment for Philadelphia-negative acute lymphoblastic leukemia. In pediatric studies, triglycerides (TGs) were affected more by PEG-asparaginase than by native L-asparaginase (10.0% vs. 5.5%). We conducted...